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INTRODUCTION
Mucopolysaccharidoses (MPSs) are a group of metabolic
diseases transmitted in an autosomal recessive fashion.
MPSs are due to deficiencies of the specific enzymes
responsible for the catabolism of dermatan sulfate, heparin
sulfate, and keratan sulfate, resulting in the accumulation of
glycosaminoglycans (GAGs). MPSs have a chronic, progres-
sive course with multisystemic involvement. The incidence
of MPSs is approximately 1/50,000 (1). As GAGs begin to
accumulate in lysosomes, functional disturbances occur in
cells, tissues, and organs. Diagnosis is based on elevated
mucopolysaccharide levels in the urine and enzyme
deficiencies in the serum or in fibroblast cultures (2).
MPS type VI (Maroteaux-Lamy syndrome) is characterized
by a deficiency of N-acetylgalactosamine-4-sulfatase, which is
responsible for the catabolism of dermatan sulfatase. The
clinical features of MPSs include coarse face, short stature,
kyphoscoliosis, upper airway thickening, hearing loss, cor-
neal opacity, hepatosplenomegaly (3), and symptoms that
vary according to the GAG accumulation sites (1). Sinus
tachycardia,atrial dilatation,valveinvolvement,endocarditis,
myocarditis, and ventricular aneurysms might be observed
due to cardiovascular system involvement (4,5). In contrast to
the other types of MPSs, there is no mental retardation in
patients with MPS type VI.
There are only a limited number of reports of heart surgery
in patients with MPSs (6,7). To the best of our knowledge, the
literature is devoid of any reports of pediatric patients with
Maroteaux-Lamy syndrome undergoing valve replacement
surgery. Herein, we present the anesthetic management of a
pediatric patient with Maroteaux-Lamy syndrome during
mitral valve replacement surgery and a discussion based on
the literature.
CASE DESCRIPTION
A 9-year-old, 96-cm-tall, and 18-kg female patient whose
sister died at the age of 14 years due to MPS type VI was
also diagnosed as having Maroteaux-Lamy syndrome at the
age of 2.5 years. She had undergone an inguinal hernia
operation in the same year that she was diagnosed, and
there were no complications in airway control or the
anesthetic course. Follow-up echocardiography when she
was three years old revealed mitral valve prolapse,
moderate mitral valve insufficiency, and a bicuspid aorta.
Although she had no limitation in exercise capacity at
earlier ages, she developed exercise dyspnea at age 7. The
patient had been treated with recombinant N-acetylgalacto-
samine-4-sulfatase enzyme (NaglazymeH, Biomarin, USA)
15 mg/kg
–1/week
–1 and digoxin drops 2.5 mg/d
–1 for
the last three years. Her preoperative echocardiography
showed an ejection fraction of 83%, along with mitral valve
prolapse, severe mitral insufficiency, mild aortic valve
stenosis, and mild aortic incompetence. Based on these
findings, mitral valve replacement surgery was scheduled.
The pre-anesthetic examination showed failure to thrive,
microcephaly, macroglossia, coarse face, corneal opacity,
gum hypertrophy, short neck, and kyphoscoliosis (Figures 1
and 2). The patient’s ASA score was class III, and her
Mallampati score was class II. The physical examination
revealed no hepatosplenomegaly. Findings in other systems
and biochemical analyses were within the normal limits,
except for exercise dyspnea. The platelet count and
coagulation tests were also in the normal ranges (platelets:
312610
9/L; prothrombin time: 12.4 seconds; international
normalized ratio: 1.06; activated partial thromboplastin
time: 39.7 seconds).
The patient was premedicated with midazolam 1 mg i.v.
in the operating room, and five-derivation ECG, SpO2, non-
invasive arterial pressure and invasive arterial pressure
were monitored. Her heart rate was 112 bpm, her arterial
blood pressure (ABP) was 105/66 mm Hg, her SpO2 was
95%, and her ECG showed a sinus rhythm. During the
induction of anesthesia, the necessary devices and materials
for adequate airway control were available, and the surgical
team was prepared to perform a tracheostomy.
Following pre-oxygenation, induction of anesthesia was
achieved with sevoflurane and midazolam 3 mg i.v. Once
ventilation was determined to be non-problematic, the
patient received propofol 50 mg i.v., fentanyl 25 mg, and
vecuronium 2 mg i.v. During direct laryngoscopy, the
Cormack-Lehane classification was determined to be class
IV. Intubation via direct laryngoscopy was unsuccessfully
attempted four times. Patient ventilation using a mask was
satisfactory between intubation attempts. The patient
was successfully intubated with a TrueView laryngoscope
(Truphatek, USA) and a No. 5 tube on the fifth attempt.
A 5-F internal jugular vein catheter with three lumens was
inserted. Following intubation, the patient’s heart rate was
140 bpm, her ABP was 92/40 mm Hg, her central venous
pressure (CVP) was 26 mm Hg, and her SpO2 was 99%. The
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693arterial blood gas parameters were as follows: pH: 7.39,
PaCO2: 41.1 mm Hg, PaO2: 200 mm Hg, SpO2: 99.1%, Hb:
12 g/dL
–1, Hct: 36.8%, glucose: 164 mg/dL
–1, lactate:
0.6 mmol/L
–1, Na: 139 mmol/L
–1, K: 3.5 mmol/L
–1, Cl:
106 mmol/L
–1, Ca: 0.92 mmol/L
–1, BE: 0.1 mmol/L
–1, and
HCO3: 24.4 mmol L
–1. Volume-controlled mechanical venti-
lation was maintained as follows: VT: 180 mL, frequency:
20 min
–1, I/E: K, FiO2: 0.5, and PEEP: 4 cmH2O. The peak
airway pressure was 22 cm H2O, and EtCO2 was 31 mm Hg.
The cardiopulmonary bypass circuit (Dideco EOSPediatric
Oxygenator, Biodevices Inc., Italy) was primed with 650 mL
of crystalloid and mannitol solution. After a median
sternotomy, anticoagulation was provided with a single dose
of 6,000 U heparin. The activated clotting time was measured
at 525 seconds. Cardiopulmonary bypass (CPB) was con-
ducted under moderate hypothermia. Myocardial protection
during aortic cross-clamping was achieved with cold crystal-
loid cardioplegia (Plegisol, Hospira Inc., USA). Following
standard mitral valve implantation (St. Jude Medical No. 25
mechanical valve, St. Jude Medical, USA), the patient was
weaned off CPB with 10 mg/kg/min of dobutamine.
Conventional ultrafiltration was also used, and a volume of
600 mL was removed.
The durationofanesthesiawas245 min,including165 min
for surgery, 50 min for cross-clamping, and 78 min for CPB.
In total, 400 mL of isotonic NaCl and 340 mL of erythrocyte
suspension were administered intraoperatively. The urine
output was 300 mL, and the bleeding volume was 150 mL.
The patient was taken to the intensive care unit under
dobutamine support with a normal sinus rhythm and the
following parameters: heart rate: 123 bpm; SpO2: 100%, ABP:
90/48 mm Hg, and CVP: +28 mm Hg. Dobutamine infusion
was administered for 3 h postoperatively. After considering
and preparing for re-intubation, the patient was intubated
when she was fully awake and met the standard extubation
criteria at the 18
th hour. She was transferred to the general
patient ward at the postoperative 48
th hour. The patient was
discharged from hospital on the 5
th postoperative day under
Coumadin treatment.
Histopathological examination of the resected mitral
valve revealed a macroscopic nodular appearance, micro-
scopic hyalinization, fibrotic thickening, and single or
clustered histiocytes with large, granular cytoplasms.
DISCUSSION
Based on the deficient lysosomal enzyme, there are six
types of MPSs. The incidences of MPSs have been reported at
between 1/25000 and 1/500000, depending on the type (1,6).
Maroteaux-Lamy syndrome accounts for 1% of all MPSs.
Treatment of MPS type VI involves recombinant N-acetylga-
lactoseamine-4-sulfatase administered p.o. Additionally, one
patient was reported who experienced a definite cure with
bone marrow transplantation (6,8). The family histories of
MPS patients are important during pre-anesthesia examina-
tions (7). InMPS patients, themostcritical problems related to
Figure 1 - Lateral position showing kyphoscoliosis and short
stature.
Figure 2 - Coarse face - one of the confirmatory feature of
Maroteaux-Lamy syndrome.
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694anesthesia are difficult intubation and airway control. It has
been reported that 25%-50% of MPS patients have pro-
blematic airways (1,5,9,10). In total, 82% of MPS patients
receiving anesthesia require urgent airway interventions (11).
A rapid tracheostomy in such cases can be difficult due to the
short neck and kyphoscoliosis. Additionally, the presence of
GAG accumulation within the entire tracheobronchial tree
must always be a consideration.
Macroglossia, deformation of the skull and facial bones,
short neck, gum disorders, limited mouth opening, the
anterior position of the larynx, and thoracic malformations
all contribute to airway control difficulty. Limited head and
neck movements and instability of the atlanto-axial joint also
require special attention during intubation (1,12,13). Previous
surgeries, especially in pediatric patientswith MPS at an early
age, might not be associated with airway problems; however,
with increasing age, morphological and anatomical changes
that occur due to mucopolysaccharide accumulation result in
airway control difficulties (1,6,14). The patient presented here
underwent complication-free inguinal hernia repair at the age
of 2.5 years under general anesthesia.
Preoperative evaluation is important, especially when
dealing with a difficult airway; in such cases, radiological
imaging might be necessary (1). In the presented case, we
did not obtain radiological imaging because we foresaw the
possibility of a difficult airway and made the necessary
preparations prior to intubation.
It was reported that loss of tonicity in the supraglottic
region due to neuromuscular blockade might cause airway
obstruction during manual ventilation. As such, it is
recommended that neuromuscular blocking agents not be
used until the airway is secure (15).
Awake intubation via fiberoptic bronchoscopy has been
suggested by some researchers (5,9,16,17). Laryngeal mask
use has also been reported (11). As we used sevoflurane for
the induction of anesthesia in this case, we were able to
preserve the patient’s spontaneous respiration. Following the
induction of anesthesia, it was observed that ventilation with
a mask was preserved before and after neuromuscular
blockade.Wewerealsopreparedforfiberoptic bronchoscopy.
Intubation was successfully accomplished on the 5
th attempt
using a TrueView laryngoscope in the neutral position.
Intravenous or general anesthesia can be used during the
surgery (1,11). When selecting the type of anesthesia,
disease stage, systemic involvement and its severity, and
airway difficulties must be considered. Although the
difficult airway issues in MPS patients undergoing non-
cardiac surgery have been resolved, the common involve-
ment of the cardiovascular system makes it more difficult to
manage anesthesia and increases the complications. It is
well known that patients with Maroteaux-Lamy syndrome
have stenoses and mitral and tricuspid valve insufficiencies
(2,6). The severity of cardiac involvement might not always
be correctly predicted clinically because of limited activity
due to limited joint movement (6).
In most individuals with MPS VI, both the liver and
spleen become enlarged due to storage of mucopolysac-
charides (hepatosplenomegaly). However, the enlarged
liver does not usually cause liver problems or lead to liver
failure. Furthermore, a significant reduction in the liver
volume is observed with enzyme replacement therapy (18).
In the patient presented here, preoperative tests revealed
normal liver function and coagulation status that might
have affected coagulation management and the choice of
anesthetic drugs during the CPB. Contrary to expectations,
no intraoperative adverse events have been reported related
to cardiac anesthesia (6).
Although this patient had serious heart valve problems,
there were no significant hemodynamic alterations follow-
ing the induction of anesthesia, either before or after CPB,
and the patient was transferred to the intensive care unit
with stable hemodynamics under dobutamine support.
Enlargement of the tongue, tonsils, and adenoids,
thickening of mucus membranes, and stenoses very deep
in the lower airway can lead to respiratory complications,
especially during the post-extubation period. Additionally,
obstructive sleep apnea can occur in such patients (19,20).
This patient was extubated 18 h after surgery and did not
experience any respiratory problems following extubation.
In conclusion, currently used anesthetic methods and drugs
can be safely used in patients with Maroteaux-Lamy, but
anesthesia protocols must be mindful that MPSs are a group of
progressive diseases, and in such patients, histories of non-
problematic airways and anesthesia management should not
mislead anesthesiologists, who should always prepare vigi-
lantly for difficult airways and systemic complications.
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